Brief: Lumibird Receives Marketing Approval In China For Its Vitra 2 Photocoagulator
April 17 (Reuters) - Lumibird SA LBIRD.PA :
* LUMIBIRD RECEIVES MARKETING APPROVAL IN CHINA FOR ITS
VITRA 2
PHOTOCOAGULATOR
* FOR YEAR 2023, LAUNCH OF VITRA 2 ALONE SHOULD ENABLE US TO
INCREASE OUR SALES BY 25%, COMPARED TO A REVENUE OF EUR 4.8
MILLION IN CHINA IN 2022 - CEO OF LUMIBIRD MEDICAL
Source text for Eikon: ID:nGNE6BqDpK
Further company coverage: LBIRD.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Lumibird SA
See all newsBrief: Lumibird - H1 Net Income Up +4.5% To EUR 5.1 Million
Brief: Lumibird Signs A Share Purchase Agreement For The Sale Of Lumibird Medical To IPG Photonics Corporation
Brief: Lumibird H1 Revenue Up +9.7% Lfl to €114.7 Mln
Brief: Lumibird Signs Agreement With Cilas
Brief: Lumibird Enters Into Exclusive Negotiations For The Sale Of Its Medical Division To IPG Photonics Corporation